Related Experiment Video
Updated: Sep 28, 2025
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.4K
Early experience with the Impella pump: Single-center registry
Alina Zubarevich1, Arian Arjomandi Rad2, Marcin Szczechowicz1
1Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
Artificial Organs
|April 4, 2022
Summary
The Impella® pump effectively supports patients with acute cardiogenic shock, enabling mobilization and neurological assessment. This study highlights its role in hemodynamic support and myocardial recovery.
Area of Science:
- Cardiology
- Mechanical Circulatory Support
Background:
- Advancements in mechanical circulatory support offer new treatment options for cardiogenic shock.
- The Impella® pump is a minimally invasive device for left ventricular unloading and circulatory support.
Purpose of the Study:
- To review institutional experience with the Impella® pump.
- To analyze major adverse events associated with Impella® device use.
Main Methods:
- Retrospective review of 32 patients who underwent Impella® implantation from January 2020 to January 2022.
- Analysis of patient demographics, indications for support, outcomes, and adverse events.
Main Results:
- All patients presented with acute cardiogenic shock (INTERMACS Class I/II).
- 81.25% of patients were mobilized on Impella® support.
- 53.1% were weaned, 31.3% bridged to durable LVAD, with 56.25% hospital discharge survival and one vascular complication.
- No strokes occurred during Impella® support.
Conclusions:
- Impella® pump is a viable option for acute cardiogenic shock requiring hemodynamic support.
- Provides effective left ventricular unloading, facilitating patient mobilization and neurological assessment.
- Demonstrates potential for myocardial recovery.
